Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Vaccines01:30

Cancer Vaccines

325
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
325

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer stem cell antigen nanodisc cocktail elicits anti-tumor immune responses in melanoma.

Journal of controlled release : official journal of the Controlled Release Society·2022
Same author

Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations.

Journal of surgical oncology·2022
Same author

Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity.

Frontiers in immunology·2022
Same author

Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells.

Cancer immunology, immunotherapy : CII·2022
Same author

Targeting cancer stem cells <i>via</i> integrin β4.

Oncotarget·2021
Same author

In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.

Journal for immunotherapy of cancer·2021

Related Experiment Video

Updated: May 26, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K

Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.

Fang Zheng1, Shan Zhang2, Alfred E Chang3

  • 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.

International Journal of Biological Sciences
|February 24, 2025
PubMed
Summary

Cancer stem cell (CSC)-targeted immunotherapy shows promise but is hindered by immune suppression. Blocking programmed cell death ligand-1 (PD-L1) on CSCs can enhance treatment efficacy.

Keywords:
antibody drug conjugatesbispecific antibodiescancer stem cellscancer vaccinesimmunosuppressionimmunotherapy

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

252

Related Experiment Videos

Last Updated: May 26, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

252

Area of Science:

  • Immunotherapy
  • Cancer Biology
  • Tumor Microenvironment

Background:

  • Cancer stem cells (CSCs) are key drivers of tumor growth and recurrence.
  • Programmed cell death ligand-1 (PD-L1) overexpression in CSCs creates an immunosuppressive tumor microenvironment (TME).
  • This immune suppression limits the efficacy of current CSC-targeted immunotherapies.

Purpose of the Study:

  • To review the role of PD-L1 in CSC properties and TME interactions.
  • To explore novel immunotherapeutic strategies targeting CSCs and overcoming immune suppression.
  • To highlight recent advancements and future directions in CSC-targeted immunotherapy.

Main Methods:

  • Review of literature on PD-L1, CSCs, and immunotherapy.
  • Analysis of CSC-targeted vaccines (DC, ND), bispecific antibodies (BiAbs), antibody-drug conjugates (ADCs), CAR-T, and NK cell therapies.
  • Examination of strategies for interrupting immunosuppression in the TME.

Main Results:

  • PD-L1 on CSCs actively contributes to immune evasion within the TME.
  • Various therapeutic modalities show potential for targeting CSCs and blocking immunosuppression.
  • Inhibiting CSC-associated signaling pathways is a viable strategy.

Conclusions:

  • Concurrent targeting of CSCs and immunosuppression is crucial for effective cancer immunotherapy.
  • Emerging strategies like CAR-T, NK cell therapy, and novel vaccines offer promising avenues.
  • Further research into PD-L1 regulation and TME crosstalk is essential for clinical translation.